



# BLUE JET HEALTHCARE LIMITED

**REGISTERED & CORPORATE :** 701 & 702, BHUMIRAJ COSTARICA,  
PLOT 1 & 2, SECTOR - 18, SANPADA, NAVI MUMBAI - 400705

**T :** 022- 41840550 / 40037603

**F :** +91 22 27814204

**E :** sales@bluejethealthcare.com

**CIN NO. :** L99999MH1968PLC014154

May 19, 2026

To,

<b>BSE Limited</b> Phiroze Jeejebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code (BSE): 544009	<b>National Stock Exchange of India Limited</b> “Exchange Plaza” Bandra-Kurla Complex, Bandra (East) Mumbai - 400051 Symbol: BLUEJET
--	--

**Sub: Intimation of Analyst and Investor call under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir / Ma'am,

In terms of the referred Regulation 30 read with Schedule III - Part A of SEBI Listing Regulations, 2015, we would like to inform you that a conference call for group of analysts and investors has been scheduled on Monday, May 25, 2026 at 04:00 PM (IST) to discuss the Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2026.

Details of the conference call are enclosed for your kind reference.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For **Blue Jet Healthcare Limited**

**Sweta Poddar**

**Company Secretary & Compliance Officer**

Unit I

3/2, Milestone, Kalyan Murbad Road, Village Varap, P.O. Box No. 5, Shahad-421 103, **Tel.:** 91 251 2280283 **Fax :** +91 251 2280567

Unit II

Plot No. B-12, C-4, E-2, MIDC, Industrial Area, Chemical Zone, Ambarnath (W) 421501. **Tel. :** +91 8956363877/8956363878

Unit III

K-4/1, Additional MIDC Road, Mahad Industrial Area, Mahad- 402309, **Tel.:** + 91 22 2207 5307 / 6192 / 1691 **Fax :** +91 22 2207 0294



## Blue Jet Healthcare Limited

### Q4 & FY26 Earnings Call on May 25, 2026, at 4:00 PM IST

**Mumbai, May 18, 2026:** Blue Jet Healthcare Ltd. (BSE- 544009, NSE- BLUEJET, ISIN: INE0KBH01020), a global, science-led, pharmaceutical company evolved as Strategic Partner for Collaboration, Development & Manufacturing of advance Pharmaceutical Intermediates and API, will host earnings call to discuss financial results for the quarter and year ended 31<sup>st</sup> March 2026 on **Monday, May 25, 2026, at 4:00 PM (IST)**.

Details of Earnings Conference Call	
<b>Day/Date</b>	Monday, May 25, 2026
<b>Time (IST)</b>	4:00 PM
<b>Universal Access</b>	+91 22 6280 1107 +91 22 7115 8008
<i>The number listed above is universally accessible from all networks and all countries</i>	
International Toll-Free Numbers	
USA	18667462133
UK	08081011573
Singapore	8001012045
Hong Kong	800964448
DiamondPass™ Link	<a href="#">Click here</a> to join with DiamondPass™ (No Wait Time)
<b>Management Representation:</b>	
Mr. Shiven Arora - Managing Director	
Mr. V.K. Singh - Chief Operating Officer	
Mr. Ganesh Karuppanan - Chief Financial Officer	
Mr. Sanjay Sinha - Deputy Chief Financial Officer	
<i>Participants are requested to dial-in 10 minutes before the scheduled time</i>	

#### **About Blue Jet Healthcare Ltd:**

Blue Jet Healthcare Ltd a specialty pharmaceutical and healthcare ingredient and intermediate company, operating under a contract development and manufacturing organization (“CDMO”) business model. The company has specialized chemistry capabilities in contrast media intermediates and high-intensity sweeteners. They have built a long-term customer base with innovator and multi-national generic pharmaceutical companies, supported by multi-year contracts. They supply a critical starting intermediate and several advanced intermediates to three of the largest contrast media manufacturers in the world, including GE Healthcare, Guerbet, and Bracco. They also supply high-intensity sweeteners to several multi-national companies, including Colgate Palmolive (India) Limited and Unilever.

#### **For further details, please get in touch with:**

**Ms. Sweta Poddar**

Blue Jet Healthcare Ltd

Email: [companysecretary@bluejethealthcare.com](mailto:companysecretary@bluejethealthcare.com)

**Diwakar Pingle | Kunal Bhoite**

EY Investor Relations

Email: [diwakar.pingle@in.ey.com](mailto:diwakar.pingle@in.ey.com) | [kunal.bhoite@in.ey.com](mailto:kunal.bhoite@in.ey.com)